Biofrontera AG: Successful Annual General Meeting with broad approval and new Supervisory Board members

Leverkusen, Germany (pta029/30.08.2024/14:35 UTC+2)

Biofrontera AG announces that all items on the agenda of the Annual General Meeting on 28 August 2024 were approved by a large majority. In addition, the Annual General Meeting elected three new shareholder representatives to the Supervisory Board.

In her speech to the shareholders, Mrs. Pilar de la Huerta, CFO of Biofrontera AG, summarized the developments of the past financial year and provided an outlook for the future: "2023 was a successful year in which we demonstrated our commitment to sustainable profitability. Furthermore, we are well positioned for long-term growth, driven by strong marketing partnerships in the European market, which will further strengthen our position as a dermatology-focused specialty pharmaceutical company".

The Annual General Meeting also elected new members to the Supervisory Board. The new Supervisory Board are Mr. Alexander Link, Dr. Helge Lubenow, Dr. Heikki Lanckriet, Mr. Hansjörg Plaggemars, Mr. Tobias Reich and Mr. Karlheinz Schmelig. At its constitutive meeting following the Annual General Meeting, the Supervisory Board elected Mr. Link as Chairman and Dr. Lubenow as Deputy Chairwoman.

Furthermore, the supervisory board committees are composed as follows: The Audit Committee is composed of Dr. Lubenow and Mr. Plaggemars, with Mr. Schmelig as Chairman. The Nomination and Remuneration Committee is composed of Mr. Link and Mr. Schmelig, and Dr. Lubenow remains Chairwoman of this committee.

"I am very pleased for the election as Chairman of the Supervisory Board and look forward to supporting Biofrontera AG on its continued growth path," commented Mr. Link on his election. "I would like to thank the resigning members of the Supervisory Board for their trusting and supportive contribution. I also look forward to a constructive working relationship with all the continuing and newly elected members, the Executive Board and the employees of Biofrontera AG".

4,788,699 voting shares were represented at the AGM, representing 78.8% of the share capital. Detailed voting results and further information are available on the company's website under "Investors/Annual General Meeting".

- end -

About Biofrontera AG

Biofrontera AG is an international specialty pharmaceutical company focused on the development and commercialization of innovative dermatological products. With a strong focus on the European market, the company strives for sustainable growth and long-term profitability.

This press release contains forward-looking statements based on current assumptions and forecasts by the management of Biofrontera AG. Known and unknown risks, uncertainties, and other factors could lead to material differences between the actual results, financial situation, or development of the company and the estimates provided here.

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor Relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	ir@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE000A4BGGM7 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate